Medicina
Departamento
Instituto Valenciano de Oncologia
Valencia, EspañaPublicaciones en colaboración con investigadores/as de Instituto Valenciano de Oncologia (212)
2024
-
Cell-cycle inhibition and immune microenvironment in breast cancer treated with ribociclib and letrozole or chemotherapy
npj Breast Cancer, Vol. 10, Núm. 1
-
Correction: SEOM-GEICAM-SOLTI clinical guidelines for early-stage breast cancer (2022) (Clinical and Translational Oncology, (2023), 25, 9, (2647-2664), 10.1007/s12094-023-03215-4)
Clinical and Translational Oncology
-
Phase II trial of afatinib in patients with advanced urothelial carcinoma with genetic alterations in ERBB1-3 (LUX-Bladder 1)
British Journal of Cancer, Vol. 130, Núm. 3, pp. 434-441
-
Safety profile of trastuzumab deruxtecan in advanced breast cancer: Expert opinion on adverse event management
Clinical and Translational Oncology
2023
-
A correlative biomarker study and integrative prognostic model in chemotherapy-naïve metastatic castration-resistant prostate cancer treated with enzalutamide
Prostate, Vol. 83, Núm. 4, pp. 376-384
-
Adjuvant Endocrine Therapy in Premenopausal Breast Cancer: 12-Year Results From SOFT
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 41, Núm. 7, pp. 1370-1375
-
Brief report: High incidence of peridiagnosis thromboembolic events in patients with BRAF-mutant lung cancer
Thrombosis Research, Vol. 232, pp. 133-137
-
CCNE1 and PLK1 Mediate Resistance to Palbociclib in HR+/HER2- Metastatic Breast Cancer
Clinical cancer research : an official journal of the American Association for Cancer Research, Vol. 29, Núm. 8, pp. 1557-1568
-
Darolutamide in Spanish patients with nonmetastatic castration-resistant prostate cancer: ARAMIS subgroup analysis
Future Oncology, Vol. 19, Núm. 12, pp. 819-828
-
Development and validation of a model to predict complex Mohs micrographic surgery in clinical practice: REGESMOSH scale
Journal of the European Academy of Dermatology and Venereology, Vol. 37, Núm. 8, pp. 1587-1594
-
Efficacy and safety of pembrolizumab in metastatic urothelial carcinoma: results from KEYNOTE-045 and KEYNOTE-052 after up to 5 years of follow-up
Annals of Oncology, Vol. 34, Núm. 3, pp. 289-299
-
Exploratory analyses of treatment subgroup interaction by PD-L1 status and according to PD-L1 expression in the JAVELIN Bladder 100 trial
Clinical and Translational Oncology
-
Genomic characterisation of hormone receptor-positive breast cancer arising in very young women
Annals of Oncology, Vol. 34, Núm. 4, pp. 397-409
-
HOPE (SOLTI-1903) breast cancer study: real-world, patient-centric, clinical practice study to assess the impact of genomic data on next treatment decision-choice in patients with locally advanced or metastatic breast cancer
Frontiers in Oncology, Vol. 13
-
Impact of the COVID-19 pandemic on the diagnosis and treatment of onco-hematologic patients: a discussion paper
Revista Espanola de Quimioterapia, Vol. 36, Núm. 1, pp. 1-25
-
Long-term outcomes of high-risk HR-positive and HER2-negative early breast cancer patients from GEICAM adjuvant studies and El Álamo IV registry
Breast Cancer Research and Treatment, Vol. 201, Núm. 2, pp. 151-159
-
Neratinib + fulvestrant + trastuzumab for HR-positive, HER2-negative, HER2-mutant metastatic breast cancer: outcomes and biomarker analysis from the SUMMIT trial
Annals of Oncology, Vol. 34, Núm. 10, pp. 885-898
-
Overall survival with neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): A randomised, double-blind, placebo-controlled, phase 3 trial
European Journal of Cancer, Vol. 184, pp. 48-59
-
SEOM-GEICAM-SOLTI clinical guidelines for early-stage breast cancer (2022)
Clinical and Translational Oncology, Vol. 25, Núm. 9, pp. 2647-2664
-
Selection of Quality Indicators for the Certification of Dermato-Oncology Units: The CUDERMA Project Delphi Consensus Study
Actas Dermo-Sifiliograficas, Vol. 114, Núm. 7, pp. 587-605